Search Results
May 12, 2026, 06:00 ET Bayesian Health Receives First-Ever FDA Clearance for Continuous AI Sepsis Monitoring
Health favorably to receive approval under the Centers for Medicare and Medicaid Services' New Technology Add-on Payment (NTAP) program starting in October 2026. The final decision on NTAP approval will be issued early August. If approved as expected, this would give hospitals deploying the cleared sepsis
More news about: Bayesian Health
Apr 17, 2026, 09:00 ET The $240 Billion Race to Rebuild Cybersecurity Before Quantum Arrives
threat detection: Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8), Commvault (NASDAQ: CVLT), NetApp (NASDAQ: NTAP), Zscaler (NASDAQ: ZS), and F5 (NASDAQ: FFIV).
More news about: Equity Insider
Mar 27, 2026, 08:09 ET Sonorous NV, Inc. Announces Leadership Transition
FDA Breakthrough Device Designation for treating pulse-synchronous tinnitus due to venous sinus stenosis, enabling prioritized review and potential NTAP eligibility.Sonorous is advancing toward IDE submission and broader market approvals.Sonorous Neurovascular remains committed
More news about: Sonorous NV, Inc.
Mar 11, 2026, 08:30 ET FDA Grants Breakthrough Device Designation to MeMed BV Flex™ Capillary Blood
interactive FDA engagement, accelerating development and regulatory review. In addition, BDD provides eligibility to Medicare's New Technology Add-on Payment (NTAP) alternative pathway and Transitional Coverage for Emerging Technologies (TCET). These programs may support broader Medicare coverage, strengthening
More news about: MeMed
Dec 03, 2025, 12:29 ET MiRus Announces First Cases with EUROPA® Posterior Cervical Fusion System with New Technology Add-on Payment (NTAP)
rhenium alloys, for treatment of the cervical and upper thoracic spine. The EUROPA® PCF system had received New Technology Add-on Payment (NTAP) from CMS earlier this year.
More news about: MiRus
Dec 03, 2025, 09:23 ET Natus announces FDA 510(k) clearance for electrographic status epilepticus diagnostic indication in BrainWatch point-of-care EEG solution
BrainWatch solution now includes electrographic status epilepticus monitoring technology, which is eligible for a New Technology Add-on Payment, or NTAP. BrainWatch will be on display Dec. 6-8 during the American Epilepsy Society annual meeting in Atlanta. Visitors to the Natus booth can learn more about
More news about: Natus Medical Incorporated
Oct 01, 2025, 10:15 ET New ICD-10-PCS Code Available for AI Sepsis Diagnostic Tools
New Technology Add-on Payment (NTAP) submission processes. "This official code recognition validates the clinical significance of advanced sepsis diagnostics
More news about: Prenosis
Oct 01, 2025, 08:00 ET Airspace Link Receives FAA NTAP Approval as UTM Provider for BVLOS Strategic Deconfliction Services
FAA Near-Term Approval Process (NTAP) Positions Cities, Federal Installations, and Commercial Operators for Proposed Part 108 Implementation DETROIT, Oct.
More news about: Airspace Link
Aug 04, 2025, 08:05 ET Inflammatix's TriVerity™ Test Secures NTAP Reimbursement from CMS for First-in-Class Severity Score Working in Concert with Bacterial and Viral Insights
diagnostics, today announced that its TriVerity™ Test has been granted New Technology Add-On Payment (NTAP) reimbursement by the Centers for Medicare & Medicaid Services (CMS) for fiscal year 2026. The NTAP decision, driven by TriVerity's novel severity score—enabled by its FDA Breakthrough Device
More news about: Inflammatix
Aug 01, 2025, 13:31 ET MiRus Receives New Technology Add-on Payment (NTAP) for EUROPA™ Posterior Cervical Fusion System
ATLANTA, Aug. 1, 2025 /PRNewswire/ -- MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for the EUROPA® Posterior Cervical System, based on it's proprietary rhenium alloys,
More news about: MiRus
Jul 09, 2025, 09:26 ET Landmark Study Shows Ultromics' EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography
aid in the detection of HFpEF, reimbursable under Medicare and commercial payer pathways, including Category III CPT Code 0932T for outpatient use and NTAP (XXE2X19) coverage for inpatient settings. Both tools operate through the EchoGo® platform, delivering diagnostic and clinical decision support from
More news about: Ultromics